<DOC>
	<DOCNO>NCT00079300</DOCNO>
	<brief_summary>RATIONALE : Biological therapy , imiquimod cream , work different way stimulate immune system stop tumor cell grow . PURPOSE : This randomized phase I trial study well imiquimod cream work treat patient basal cell skin cancer .</brief_summary>
	<brief_title>Imiquimod Cream Treating Patients With Basal Cell Skin Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare level apoptosis patient basal cell skin cancer treat v without imiquimod 5 % cream . Secondary - Compare level apoptosis patient treat drug two different administration schedule . OUTLINE : This randomize , double-blind , placebo-controlled , parallel-group study . Patients undergo fine needle aspiration punch biopsy target lesion . Patients randomize 1 8 treatment arm begin therapy within 30 day biopsy . - Arm I : Patients apply topical imiquimod target lesion every 12 hour day 1 2 total 4 dos . - Arm II : Patients apply topical placebo target lesion every 12 hour day 1 2 total 4 dos . - Arm III : Patients apply topical imiquimod target lesion every 24 hour day 1-4 total 4 dos . - Arm IV : Patients apply topical placebo target lesion every 24 hour day 1-4 total 4 dos . - Arm V : Patients apply topical imiquimod target lesion every 12 hour day 1-4 total 8 dos . - Arm VI : Patients apply topical placebo target lesion every 12 hour day 1-4 total 8 dos . - Arm VII : Patients apply topical imiquimod target lesion every 24 hour day 1-8 total 8 dos . - Arm VIII : Patients apply topical placebo target lesion every 24 hour day 1-8 total 8 dos . All patient undergo excision target tumor within 18-30 hour last topical treatment . Patients follow 7-14 day . PROJECTED ACCRUAL : A total 48 patient ( 8 per treatment arm 4 per placebo arm ) accrue study .</detailed_description>
	<mesh_term>Carcinoma , Basal Cell</mesh_term>
	<mesh_term>Skin Neoplasms</mesh_term>
	<mesh_term>Imiquimod</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm basal cell skin cancer Superficial nodular disease No aggressive disease At least 1 lesion least 7 mm diameter meet follow criterion : Primary tumor ( recurrent previously treat disease ) Located scalp , face ( include ear ) , trunk , proximal extremity Qualifies surgical excision primary therapy PATIENT CHARACTERISTICS : Age 18 Performance status Not specify Life expectancy Not specify Hematopoietic Not specify Hepatic Not specify Renal Not specify Cardiovascular No evidence clinically significant unstable medical condition would adversely affect blood circulation Other No dermatological disease ( e.g. , psoriasis eczema ) treatment site may exacerbate treatment imiquimod interfere examination No febrile viral infection within past 4 week No evidence clinically significant unstable medical condition would adversely affect immune function PRIOR CONCURRENT THERAPY : Biologic therapy More 4 week since prior interferon , interferon inducer , immunomodulators No concurrent interferon , interferon inducer , immunomodulators Chemotherapy More 6 month since prior anticancer chemotherapy No concurrent anticancer chemotherapy Endocrine therapy More 4 week since prior oral inhale ( 600 mcg/day fluticasone equivalent ) corticosteroids More 4 week since prior topical steroid target tumor Concurrent topical steroid nontarget area allow provided amount use â‰¤ 2 g fluorinated steroid daily &gt; 1 week 6 g beclomethasone &gt; 1 week No concurrent oral inhale corticosteroid Radiotherapy Not specify Surgery More 4 month since prior biopsy Other More 4 week since prior immunosuppressive therapy More 4 week since prior cytotoxic investigational drug No concurrent immunosuppressive therapy No concurrent cytotoxic investigational drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>basal cell carcinoma skin</keyword>
</DOC>